Navidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $4.29 million versus the consensus estimate of $4.06 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.